Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (121)	1/5/2007 10:54:11 PM
From: zeta1961	Read Replies (1) \| Respond to of 250

Something is very fishy..there was an ELN analyst who made this statement during the Tysabri debacle.. Genentech is not only an A+ biotech but also deserves kudos for symantecs..I found this at Ihub But Pellegrino of Genentech insisted to CNNMoney.com that the pertuzumab study had made its endpoint. She also said she hadn't discussed the matter with Kantor and had not seen his note. "The endpoint of the study was to estimate what the improvement in progression-free survival would be," said Pellegrino. "I don't think it's accurate to say it missed its endpoint. We met the endpoint of estimating progression-free survival." So 'we' were successful in reaching trial design consensus but the study wasn't successful?..it's too bad that Kantor seems to have a bad reputation..people seem to have spent more time bashing him than rightfully Dna for this gratuitous PR PGS response was great.. investorshub.com investorshub.com